How to use the speech recognition tool?
A Long-term Follow-up Study to Evaluate the Safety and efficacy of Retinal Gene Therapy in Subjects with choroideremia treated previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study.
Status of the trial: Active, Recruiting
Orphan Drug Recognition: Yes
- Opening Date: 2017-01-01
- Closing Date: 2027-03-27
Inclusion: Subjects are willing and able to give informed consent for participation in the study, and have received a sub-retinal injection of AAV2-REP1 for CHM in an antecedent study.
Exclusion: There are no exclusion criteria for this study.
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
- Retinal Rare Eye Diseases (WG1)
This ERN is supported by: